HPTN 084 Study
HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Rationale
PrEP may only reach its full potential for HIV prevention with agents that do not depend on daily or near-daily pill-taking. The development of alternative agents for PrEP, and/or more adherence-friendly schedules for currently available agents, could increase prevention choices and increase acceptability. Long-acting injectable agents have the potential to prevent HIV acquisition without relying on adherence to a daily oral regimen.
Investigators
- Dr Carrie-Anne Mathew, Co-Principal Investigator
- Dr Elizabeth Roos, Co-Principal Investigator
- Prof Sinead Delany-Moretlwe, Sub Investigators
- Dr Monique Da Fonseca, Sub Investigators
- Dr Juliet Vimbai Rundogo, Sub Investigators
- Dr Nicole Poovan, Sub Investigators
Media Coverage
- National Institutes of Health Press Release, 23 July 2024: Long-acting injectable cabotegravir for HIV prevention is safe in pregnancy
Latest Update
July 2024
For more details about HPTN 084 study please email rhicomms@wrhi.ac.za
Click here for further details regarding the HPTN 084 study.
